HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.

Heilongjiang ZBD Pharmaceutical Co., Ltd.

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
12 ^CNY	+5.36%		+9.59%	-1.32%

Apr. 29	Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Heilongjiang ZBD Pharmaceutical Co., Ltd.

Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets	Feb. 20	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug	23-09-26	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index	23-09-18	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index	23-09-18	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	23-05-10	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million.	23-05-09	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	23-04-04	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	23-01-03	CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies	22-12-06	MT
Heilongjiang ZBD Gets Approval for Traditional Medicine Product	22-11-04	MT
Heilongjiang ZBD’s Anti-Pulmonary Fibrosis Drug Gets U.S. Patent	22-11-02	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	22-10-10	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	22-08-02	CI
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. from Hulin Longpeng Investment Center.	22-06-09	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	22-06-09	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-06-08	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-29	CI

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

Duration

Period

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

More charts

HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.	-1.32%	1.56B
ELI LILLY AND COMPANY	+26.47%	664B
NOVO NORDISK A/S	+26.74%	567B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.35%	330B
ABBVIE INC.	+4.23%	286B
ASTRAZENECA PLC	+13.43%	234B
NOVARTIS AG	+4.71%	199B
ROCHE HOLDING AG	-9.53%	196B
AMGEN INC.	-4.04%	148B

Other Pharmaceuticals